Clinical Trial: Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06386302) titled 'Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia' on April 23.

Brief Summary: To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.

Study Type: Interventional

Condition: * AML

* Acute Myeloid Leukemia

Intervention: * Drug: Chidamide

30 mg/d orally twice-weekly

* Drug: Venetoclax

100 mg d1 200 mg d 2 400 mg d3-d28 Orally

* Drug: azacitidine

75 mg/m 2 /d subcutaneous injection or IV d1-d7

Recruitment Status: Not Yet Recruiting...